We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.16 | 1.48% | 147.8995 | 148.13 | 144.54 | 146.01 | 9,747,868 | 23:36:17 |
From Apr 2021 to Apr 2024
By Michael Dabaie
Johnson & Johnson's Janssen Pharmaceutical Cos. said a study of Tremfya met its primary objective in psoriatic arthritis.
The company said the latest Phase 3 data for Tremfya demonstrated significant and durable improvement in signs and symptoms of active psoriatic arthritis while maintaining its safety profile in patients with inadequate response to tumor necrosis factor inhibition.
Results showed significantly higher proportions of patients treated with Tremfya had improvement in joint signs and symptoms and complete skin clearance versus placebo at week 24. Improvements in signs and symptoms of PsA were maintained or numerically increased through one year among Tremfya-randomized patients, the company said.
Tremfya is approved in the U.S. for moderate to severe plaque psoriasis and active psoriatic arthritis.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 03, 2021 08:49 ET (13:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
